Time has come:HTDS.014x.016.Alert,cancer drug Tubercin,test results any day from now to middle of December per last news.Time is getting close.A rally soon IMO.
Read bold.
TESTING:
The testing being conducted at the Denver Veteran’s Affairs Medical Center and the University of
Colorado Health Science Center is ahead of schedule. The testing began 7/1/04 and the
agreement calls for a formal report of results after six months. We can only release the fact that
the results have been more than favorable and HTTD is expecting a formal report of testing
results by mid December. The testing results will be released as soon as HTTD receives them.
HTTD has continued to test Tubercin® in FDA approved facilities under FDA guidelines. HTTD
has and will continue to pay for this testing. We are all aware of the tremendous results of
administering Tubercin® to patients in South Korea. Our goal with Tubercin® has not changed;
to aggressively advance the testing of Tubercin® in the U.S., make strategic decisions and to be
involved in negotiations with major drug firms within 18 months.
Delray Beach, Fla., November 22, 2004 – Hard to Treat Diseases
Incorporated (HTTD) (Pink Sheets:HTDS) --- Announces:
Update from Hard to Treat Diseases, Incorporated
This update is an opportunity to keep our shareholders abreast of current developments at HTTD.
The three major areas discussed below are as follows:
LITIGATION
TESTING
IFS / RECYCLING STATUS
If you need background or additional information in order to get up to speed, please refer to the
following captions listed at the top of HTTD’s webpage:
PRESS RELEASE: Letter to Shareholders, dated 7/28/04
MOTION FOR EMERGENCY INJUNCTION, dated 9/29/04
ORDER TO DISMISS, dated 11/2/04
LITIGATION:
HTTD is currently involved in litigation with Shinn Capital Group, Inc. (“Shinn Capital”) and two
former HTTD executives, Ronald Shinn (“Shinn”) and Gerry G. Knight (“Knight”) in Florida
Federal Court regarding the right and license to Tubercin®. On 9/29/04 HTTD filed a Motion for
an Emergency Preliminary Injunction against the defendants for their attempts to use a new
corporation, ArTec, Inc. (“ArTec”) to further damage HTTD and misappropriate Tubercin®. Both
Shinn Capital and ArTec are corporations owned and controlled by Shinn. On 10/7/04 the
Federal Judge denied HTTD’s request for emergency relief, since the court found there to be no
emergency in the matter. The motion was referred to a Federal Magistrate Judge for a report and
recommendation on whether a preliminary injunction should issue. A hearing was scheduled by
the Magistrate Judge this November regarding the injunction. The hearing was continued by the
Magistrate Judge before the scheduled date pending additional information from the Federal
Judge. HTTD has supplied the Federal Court with all necessary information on a timely basis. If
and when a hearing is rescheduled, the ruling of the Federal Judge will immediately be released
by HTTD when received.
Both a hearing for Partial Summary Judgement and a trial commencement date have been
scheduled by the Federal Court during the first quarter of 2005. These dates are set irrespective
of whether or not HTTD receives an injunction against Shinn Capital, Shinn, and Knight.
Details regarding the dismissal of the Oklahoma case by Shinn Capital will be described in a
press release this week.
We are fully confident that the United States court system will rule fully based on the facts. If the
court rules in favor of HTTD, we will continue to maintain control of Tubercin® and all related
patent applications and patent letters owned now and in the future.
We could fill HTTD’s website with the affidavits, interrogatory responses and deposition
testimonies of both Shinn and Knight, but while litigation is open this case should not be tried in
the public arena and undermine the authority of the Federal Judge. The information supplied by
Shinn and Knight clearly show their ineptitude at running a public company, their total disregard
for shareholders, fiduciary responsibilities, the truth and the inescapable conclusion that they
conspired to steal HTTD’s money and damage its shareholders.
A basic element of running a public company and a regulation of the SEC is that you cannot
mislead investors. Our shareholders have asked why Shinn has not, to this date, disclosed on
his new companies website or press releases the fact that he is involved in litigation regarding the
rights to Tubercin®. We don’t have an answer.
TESTING:
The testing being conducted at the Denver Veteran’s Affairs Medical Center and the University of
Colorado Health Science Center is ahead of schedule. The testing began 7/1/04 and the
agreement calls for a formal report of results after six months. We can only release the fact that
the results have been more than favorable and HTTD is expecting a formal report of testing
results by mid December. The testing results will be released as soon as HTTD receives them.
HTTD has continued to test Tubercin® in FDA approved facilities under FDA guidelines. HTTD
has and will continue to pay for this testing. We are all aware of the tremendous results of
administering Tubercin® to patients in South Korea. Our goal with Tubercin® has not changed;
to aggressively advance the testing of Tubercin® in the U.S., make strategic decisions and to be
involved in negotiations with major drug firms within 18 months.
HTTD has been actively testing Tubercin® and moving the drug forward. HTTD will not fill it’s
website with fluff such as old testimonials about Tubercin® and events in South Korea. We all
know the wonderful results achieved in South Korea.
HTTD will soon release the results achieved in the U.S. for the advancement of Tubercin®, to
benefit those patients in need of the drug and to benefit our shareholders.
INTERNATIONAL FOAM SOLUTIONS (IFS):
HTTD owns 20% of IFS. IFS is now in the final stage of a contract with China in order for China
to purchase and construct its first major polystyrene recycling plant. This has been an enormous
and time consuming task with China that is nearly complete. This will be the first of numerous
recycling plants to be constructed in China that will utilize the technology, machinery and solvents
to be purchased from IFS.
IFS is currently negotiating with three large domestic corporations that all plan to construct
recycling plants utilizing technology and products purchased from IFS. In addition, the current
customer base of IFS has grown at a steady pace regarding the sale of small machines and
solvents.
I’m working with Mr. Katz to keep IFS focused on closing a major contract that will benefit HTTD.
Our shareholders will be notified as soon as the first major contract is signed by IFS.
F
eel free to call me if you have any questions or concerns regarding the Company or my
performance.
Colm J. King
President and CEO
Hard to Treat Diseases, Incorporated
(561) 272-6900
www htdsotc com
Market Data 
Markets 
AI
